1994
Laboratory markers and the risk of developing HIV-1 disease among injecting drug users
Alcabes P, Selwyn P, Davenny K, Hartel D, Buono D, Schoenbaum E, Klein R, Friedland G. Laboratory markers and the risk of developing HIV-1 disease among injecting drug users. AIDS 1994, 8: 107-116. PMID: 7912083, DOI: 10.1097/00002030-199401000-00016.Peer-Reviewed Original ResearchConceptsCD4 lymphocyte countHIV-1-related outcomesLow CD4 lymphocyte countCD4 lymphocyte numbersPyogenic bacterial infectionsHIV-1 diseaseLymphocyte countLaboratory markersLymphocyte numbersClinical eventsAIDS diagnosisRelative riskDrug usersBacterial infectionsHIV-1-associated diseaseBeta 2M levelsSerum beta 2M levelsDifferent laboratory markersMultiple constitutional symptomsAIDS riskMethadone treatment programsPredictors of progressionHIV-1 infectionLow platelet countLower leukocyte counts
1991
Survival differences in patients with AIDS.
Friedland G, Saltzman B, Vileno J, Freeman K, Schrager L, Klein R. Survival differences in patients with AIDS. JAIDS Journal Of Acquired Immune Deficiency Syndromes 1991, 4: 144-53. PMID: 1987352.Peer-Reviewed Original ResearchConceptsPneumocystis carinii pneumoniaFavorable survivalCarinii pneumoniaMale sexYounger ageRisk behaviorsInitial AIDS diagnosisSingle medical centerIntravenous drug usePoint of diagnosisInitial AIDSMedian survivalAIDS diagnosisBlack raceSurvival differencesKaposi's sarcomaMedical CenterClinical carePatientsDrug useAIDSSurvivalDiagnosisPowerful predictorMonths